Canaccord raised the firm’s price target on Acadia Pharmaceuticals to $40 from $38 and keeps a Buy rating on the shares. The firm said they like the continued execution on Nuplazid with the lower end of its 2023 outlook raised. With the company executing well, they also point to upcoming Phase 3 data in 1Q24 for pimavanerisn in negative symptoms of schizophrenia (NSS).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals upgraded to Buy from Neutral at Mizuho
- Acadia Pharmaceuticals price target raised to $42 from $39 at JMP Securities
- Acadia Pharmaceuticals sees FY23 NUPLAZID net sales $537.5M-$545M
- Acadia Pharmaceuticals sees Q4 DAYBUE net sales $80M-$87.5M
- Acadia Pharmaceuticals reports Q3 EPS (40c), consensus (43c)
Questions or Comments about the article? Write to editor@tipranks.com